Responsive Ad Slot




Buhay Pinay



Philippine News

Join us at Facebook!

Study shows BioNTech vaccines give 10x more protection than Sinovac

16 July 2021

By The SUN 

BioNTech gives 10x more protection than Sinovac, the study shows

People who received BioNTech’s coronavirus vaccine have ten times more antibodies than those who got Sinovac, a study by the University of Hong Kong has revealed, indicating a much higher level of protection against future infections.

The result, published on Lancet Microbe on Thursday, was based on a study of 1,442 healthcare workers who received Covid-19 jabs. From this group, the HKU team obtained final results from 93 individuals, aged 26 to 65. Sixty-three had the BioNTech vaccine while 30 received Sinovac.


Using two tests that measure antibodies binding to a virus, the researchers found that antibody levels for those who received BioNTech “rose substantially after the first dose and then rose again after the second dose of vaccination.”

Those who were vaccinated with Sinovac, on the other hand, had antibodies that rose from low after the first jab, to moderate after the second.

Call now!

The study adds to the growing proof that vaccines using mRNA technology, such as BioNTech and Moderna, offer better protection against the coronavirus and its variants than those developed using the more traditional inactivated virus parts, such as Sinovac.

The two vaccines are the only ones offered in Hong Kong currently.

Pindutin para sa detalye

Despite the survey results, HKU epidemiologist Ben Cowling, one of the report’s authors, said people should still get vaccinated with Sinovac if there was no other option because some protection is better than none.

Cowling told reporters: "It is clearly better to go and get vaccinated with an inactivated vaccine than to wait and not get vaccinated.”


“Many, many lives have been saved by the inactivated vaccine.”

Cowling says go with BioNTech if you can, but Sinovac is better than no protection

But if you have a choice, as in Hong Kong, Cowling said it is still advisable to go for BioNTech.  

“In Hong Kong, when we’re thinking about the alternatives, I would advise if you can get the BioNTech vaccine, get the BioNTech vaccine. I’ve said that all along, because it’s a more effective vaccine, gives a higher protection of vaccine that will likely last for longer,” he said.


“But if for some reason you can’t receive the BioNTech vaccine, or there’s another reason you don’t want to get the BioNTech vaccine, still it’s better to get the Sinovac vaccine than to not get vaccinated.”

To address the disparity in the levels of protection given by the two vaccines, Cowling suggested that booster shots be given, and those who received Sinovac should get priority.


"The priority would be boosters for people who received Sinovac while boosters for people who initially received BioNTech might not be so urgent," he said.

Cowling said he was concerned that antibodies may no longer be present in those who had the Sinovac vaccine after three or six months.

However, he said the focus now should still be on vaccinating as many people as possible. Giving booster doses, according to him, should start only by the end of the year or by early next year.

Don't Miss